Results 11 to 20 of about 16,939 (115)

Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial [PDF]

, 2011
<b>Background</b> The immune modulating properties of statins may benefit smokers with asthma. We tested the hypothesis that short-term treatment with atorvastatin improves lung function or indices of asthma control in smokers with asthma.<
Chaudhuri, Rekha, Lloyd, Suzanne M., Spears, Mark, Thomson, Neil C., Iona Donnelly, Lloyd, Suzanne M, Jolly, Lisa, Mair, Frances, Braganza Georgina, Mair Frances, Weir Christopher J, Frances Mair, Mark Spears, McSharry, Charles, Lafferty Jane, Christopher J Weir, Lloyd Suzanne M, McSharry Charles, Lisa Jolly, Braganza, Georgina, Weir, Christopher J., Spears, Mark; id_orcid, Lafferty, Jane, Rekha Chaudhuri, Charles McSharry, Thomson Neil C, Georgina Braganza, Thomson, Neil C, Chaudhuri Rekha, Neil C Thomson, Jane Lafferty, Suzanne M Lloyd, Spears Mark, Donnelly, Iona, Weir, Christopher J; id_orcid, Donnelly Iona, Jolly Lisa   +36 more
core   +2 more sources

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importnace of Lp(a) [PDF]

, 2012
We carried out a genome-wide association study (GWAS) of LDL-c response to statin using data from participants in the Collaborative Atorvastatin Diabetes Study (CARDS; n = 1,156), the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT; n = 895), and the ...
Postmus, Iris, Colhoun, H.M., McKeigue, Paul M, Stanton, A.V., Trompet, S., Hyde, Craig, Colhoun, Helen M, Caulfield, M., Shields, Denis C., Hitman, Graham A, CARDS, Poulter, Neil, Shields, D.C., Sever, P., Chatterjee, Aurobindo, Trompet, Stella, Durrington, Paul N, Deshmukh, H.A., DeMicco, D.A., Calle, Roberto A., Hitman, Graham A., Neil, A., McKeigue, Paul M., Fuller, John H., Postmus, I., Hitman, G.A., DeMicco, David A., Johnson, T., ?, ?, Calle, Roberto A, Betteridge, D.J., Livingstone, Shona, Ford, Ian, McKeigue, P.M., Stanton, Alice V., Jukema, J.W., Johnson, Toby, Durrington, Paul N., Neil, Andrew, PROSPER Investigators, Livingstone, S., Jukema, J. Wouter, ASCOT, Colhoun, Helen, Ford, I., Sever, Peter, Fuller, J.H., Jukema, J Wouter, Caulfield, Mark, Fuller, John H, Chatterjee, A., Deshmukh, Harshal A, Calle, R.A., Hyde, C., Charlton-Menys, V., Poulter, N., Charlton-Menys, Valentine, DeMicco, David A, Betteridge, D John, McKeigue, Paul M.; id_orcid, Betteridge, D. John, Durrington, P.N., Colhoun, Helen M., Shields, Denis C, Deshmukh, Harshal A., Stanton, Alice V   +65 more
core   +1 more source

Comparison of the Antimicrobial Effect of Atorvastatin and Nano-Atorvastatin Mouthwash on Aggregatibacter Actinomycetemcomitans: An in vitro Study [PDF]

Journal of Dentistry
Background: The emergence of resistance, side effects, and the high cost of drugs indicates a need for other therapeutic alternatives with similar properties but fewer side effects.Purpose: The present study aims to compare the antimicrobial effect of ...
Atefeh Ramezani, Tahura Etezadi, Hamidreza Goli, Nafas Daraei, Majid Saeedi, Melika Mollaei, Alireza Sedighi, Abolfazl Hosseinnattaj, Hodis Ehsani   +8 more
doaj   +1 more source

Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg)::Design and Rationale of the ODYSSEY OPTIONS Studies [PDF]

, 2014
The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double-blind, active-comparator, 24-week studies evaluating the efficacy and safety of alirocumab, a fully human monoclonal ...
Peter H. Jones, Robinson, Jennifer G., Hanotin, Corinne, Du, Yunling, Jones, Peter H., Harold E. Bays, Corinne Hanotin, Yunling Du, Colhoun, Helen M., Donahue, Stephen, Jennifer G. Robinson, Helen M. Colhoun, Stephen Donahue, Bays, Harold E.   +13 more
core   +1 more source

Atorvastatin suppresses lipopolysaccharide-induced inflammation in human coronary artery endothelial cells

Brazilian Journal of Pharmaceutical Sciences, 2022
The present study was designed to examine the effects of atorvastatin on vascular inflammatory responses in human coronary artery endothelial cells(HCAECs), when challenged by lipopolysaccharide (LPS), a Toll-like receptor-4 (TLR4) ligand.
Zhen Tian, Zhitao Li, Tian Guo, He Li, Yanshuang Mu   +4 more
doaj   +1 more source

Atorvastatin Induces FXR and CYP7A1 Activation as a Result of the Sequential Action of PPARγ/PGC-1α/HNF-4α in Hep3B Cells

The Korean Journal of Gastroenterology, 2021
Backgrounds/Aims: PPARγ, farnesoid X receptor (FXR) and CYP7A1 are associated with solubility of bile. This study was performed to understand a mechanism and interactions of statin-induced PPARγ, PGC-1α and HNF-4α related to the statin-induced activation
Jin Lee, Eun Mi Hong, Jang Han Jung, Se Woo Park, Sang Pyo Lee, Dong Hee Koh, Hyun Joo Jang, Sea Hyub Kae   +7 more
doaj   +1 more source

A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.

PLoS ONE, 2021
BackgroundAlthough accumulating evidence suggests a more extensive reduction of low-density lipoprotein cholesterol (LDL-C), it is unclear whether a higher statin dose is more effective and cost-effective in the Asian population.
Ji Bak Kim, Woo Hyuk Song, Jong Sung Park, Tae-Jin Youn, Yong Hyun Park, Shin-Jae Kim, Sung Gyun Ahn, Joon-Hyung Doh, Yun-Hyeong Cho, Jin Won Kim   +9 more
doaj   +1 more source

Changes in Blood Lipids and Enzymatic Reactions in Response to Atorvastatin Administration Following a High-Fat Diet in a NAFLD Rat Model

Medical Laboratory Journal, 2022
Background and objectives: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease caused by the accumulation of large amounts of fat in the hepatocytes.
Zahra Eslami, Yahya Mohammadnajad Panah kandi, Alireza Norouzi, Abdorreza Eghbal Moghanlou, Mehdi Sheikh arabi, Vahideh Kazeminejad, seyedeh somayeh hosseini alarzi, Aref Saeidi, Hamidreza Joshaghani   +8 more
doaj  

Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/− Mice

Translational Oncology, 2017
Atorvastatin is widely used to lower blood cholesterol and to reduce risk of cardiovascular disease–associated complications. Epidemiological investigations and preclinical studies suggest that statins such as atorvastatin have antitumor activity for ...
Ming Hong Shen, Paulina Samsel, Louise L. Shen, Kalin Narov, Jian Yang, Julian R. Sampson   +5 more
doaj   +1 more source

Pharmacokinetics and Genetic Factors of Atorvastatin in Healthy Korean Subjects

Frontiers in Genetics, 2022
Background: Statins are the most popular agents for the primary and secondary prevention of cardiovascular disease; however, the pharmacokinetic parameters and associated genetic factors in the Korean population have not been fully elucidated. This study
Serim Kim, Jong Do Seo, Yeo-Min Yun, Yeo-Min Yun, Hanah Kim, Hanah Kim, Tae-Eun Kim, Taeheon Lee, Tae-Rim Lee, Jun Hyung Lee, Eun-Hae Cho, Chang-Seok Ki   +11 more
doaj   +1 more source